1Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, SAUDI ARABIA
2Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, SAUDI ARABIA
3Medical Research Center, Jazan University, Jazan, SAUDI ARABIA
4Department of Clinical Pharmacy, Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan, SAUDI ARABIA
5Department of Biochemistry, College of Veterinary Medicine, Sadat City University, Sadat, EGYPT
6Department of Pharmacology, Dr. Joseph Mar Thoma Institute of Pharmaceutical Sciences and Research, Alappuzha, INDIA
Corresponding author.
Author Notes
Copyright and License information
ABSTRACT
Background
Epilepsy is a neurological disorder characterized by anomalous brain activity, convulsionsandoddbehaviour.Tenpyrrolecarbohydratebasedanalogues(Va-Vj)weresynthesized with amide as intermediate in the current research with the goal of reducing convulsions and seizures.
Materials and Methods
The newly developed compounds were synthesized. Numerous methods (IR, NMR, mass, elemental analysis, etc.,) were used to characterize these substances. Several models were used to test each of these molecules for anticonvulsant activity. By using the rotarod and ethanol potentiation techniques, neurotoxicity was also evaluated. The study meticulously examined each parameter and showed ADME predictions for each of the 10 congeners that were produced. In addition, studies on molecular docking employed the GABA-A target protein.
Results
Anticonvulsant screening results identified compounds Ve, Vd, Vc and Va as the most efficacious of the series. All synthesized equivalents largely passed the neurotoxicity test. The results of molecular docking revealed significant interactions at the active site of GABA-A with Ile C:242, Asp C:424, Phe D:307, Arg C:250 Trp C:241 and Phe C:240 and the outcomes were good and in agreement with in vivo findings.
Conclusion
The study’s findings showed that some substances had promising anticonvulsant properties that were comparable to those of the standard drug. The highly active novel anticonvulsant analogues may therefore represent a possible lead and additional studies may result in a potential new drug candidate.